Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization

Stéphane Zalinski, Olivier Scatton, Bruto Randone, Olivier Vignaux, Bertrand Dousset

INTRODUCTION
Most patients with hepatocellular carcinoma (HCC) are not eligible for curative treatment, which is resection or transplantation. Two recent series have emphasized the potential benefits of preoperative arterio-portal embolization prior to surgical resection of such tumours. This preoperative strategy offers a better disease free survival rate and a higher rate of total tumor necrosis. In case of non resectable HCC it is now widely accepted that transarterial chemoembolization (TACE) leads to a better survival when compared to conservative treatment. Thus, the question remains whether combined portal vein embolization (PVE) may enhance the proven efficiency of TACE in patients with unresectable HCC. We herein report the case of a 56-year-old cirrhotic woman with a voluminous HCC unsuitable for surgical resection. Yet, complete tumour necrosis and prolonged survival could be achieved after a combined porto-arterial embolization. This case emphasizes the potential synergistic effect of a combined arterio-portal embolization and the hypothetical survival benefit of such a procedure, in selected patients, with HCC not suitable for surgery or local ablative therapy.

Key words: Hepatocellular carcinoma; Sequential arterio-portal embolization; Palliative treatment

Peer reviewers: Diego Garcia-Compean, MD, Professor, Faculty of Medicine, University Hospital, Department of Gastroenterology, Autonomous University of Nuevo Leon, Ave Madero y Gonzalitos, 64700 Monterrey, NL, Mexico; Ahmed Helmy, PhD, Department of Liver Transplantation, King Faisal Specialist Hospital & Research Center, Dept. of Liver transplantation, Hepatobiliary & Pancreatic Surgery, King Faisal Specialist Hospital & Research Center, MBC 72, Riyadh 3354, Saudi Arabia

Zalinski S, Scatton O, Randone B, Vignaux O, Dousset B. Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. World J Gastroenterol 2008; 14(44): 6869-6872 Available from: URL: http://www.wjgnet.com/1007-9327/14/6869.asp DOI: http://dx.doi.org/10.3748/wjg.14.6869

Abstract
Most patients with hepatocellular carcinoma (HCC) are not eligible for curative treatment, which is resection or transplantation. Two recent series have emphasized the potential benefits of preoperative arterio-portal embolization prior to surgical resection of such tumours. This preoperative strategy offers a better disease free survival rate and a higher rate of total tumor necrosis. In case of non resectable HCC it is now widely accepted that transarterial chemoembolization (TACE) leads to a better survival when compared to conservative treatment. Thus, the question remains whether combined portal vein embolization (PVE) may enhance the proven efficiency of TACE in patients with unresectable HCC. We herein report the case of a 56-year-old cirrhotic woman with a voluminous HCC unsuitable for surgical resection. Yet, complete tumour necrosis and prolonged survival could be achieved after a combined porto-arterial embolization. This case emphasizes the potential synergistic effect of a combined arterio-portal embolization and the hypothetical survival benefit of such a procedure, in selected patients, with HCC not suitable for surgery or local ablative therapy.

© 2008 The WJG Press. All rights reserved.
resection or local ablative therapy. However, the question remains whether combined portal embolization may enhance the proven efficiency of TACE in patients with unresectable hepatocellular carcinoma (HCC).

We herein report the case of a cirrhotic patient with advanced HCC in whom complete tumor necrosis and prolonged survival were observed following a combined porto-arterial embolization.

**CASE REPORT**

A 56-year-old woman with alcoholic cirrhosis, Child-Pugh A6 presented with an 80 mm HCC stage III. The tumor developed in the right hepatic lobe, impinging on the median hepatic vein and in contact with the right glissonian pedicle (Figure 1A). There were two satellite nodules but the left hepatic lobe was free of tumor. The right portal vein was patent. The patient had stopped alcohol intake for 3 mo before admission. There was no past history of encephalopathy, ascites or upper gastrointestinal bleeding during stage I oesophageal varices. The clinical examination was normal. Liver biochemistry showed: A 74% prothrombin time, normal albumin level, bilirubin 50 μmol/L (N < 17), ASAT/ALAT: 59/66 UI/L (N < 40), gamma glutamyl transferase: 204 UI/L (N < 140), alkaline phosphatase: 105 UI/L (N < 80), platelet count was 126 000/mm³. Alpha-foeto protein level was 108 μg/L (N < 5). The diagnosis of established alcoholic cirrhosis was confirmed by a percutaneous liver biopsy. As the surgical strategy was a right hepatectomy removing the median hepatic vein and the patient underwent a right portal vein embolization (PVE) prior to surgery (Figure 2A and B). After 4 wk the left lobe had gained 40%. During surgery, intra-abdominal exploration revealed moderate to severe portal hypertension with an enlarged spleen, mild ascites and dilated splanchic veins. The liver appeared cirrhotic with regeneration nodules. Intraoperative ultrasound confirmed an 8 cm HCC, mainly involving segment V and VIII, invading the median hepatic vein and close to the right glissonian pedicle. Peroperative observation precluded liver resection and separate biopsy of both tumor and liver parenchyma was done before abdominal closure. In view of previous right PVE, intra-arterial chemoembolization was thought to be unsafe and a supportive medical care was decided. During follow-up, a 20 mm intra-tumoral aneurysm of right arterial branch was diagnosed on computer tomography (CT) scan (Figure 1B), most probably related to an arterial trauma during intraoperative tumor biopsy. A supra-selective arterial embolization with coils was then undertaken with complete obliteration of the arterial aneurysm on control angiography (Figure 3A and B). A control CT scan performed 3 mo later showed complete necrosis of the tumor (Figure 1C) as suggested by return of alpha-foeto protein to normal value (6.8 μg/L). Disease-free survival lasted for two years. Multiple intra-hepatic and bone recurrence was diagnosed on progressive increase of alpha-foeto-protein level. The patient ultimately died after a follow-up of three years.

**DISCUSSION**

In up to 90%, HCC develop in cirrhotic patients whose impaired liver function precludes major liver resections if FLR is less than 40%[19]. First reported by Makuuchi et al[13], PVE can be performed safely[14] in order to induce a homolateral liver parenchyma atrophy and a hypertrophy of the FLR, allowing resection in patients with large tumors or abnormal liver function[20]. Yet, this technique was initially described for patients with Klatskin tumors[19] and its’ application to cirrhotic patients with HCC is debated by some authors who rather recommend a preoperative combined arterio-portal embolization[16]. HCC being hypervascular tumours mainly fed by an arterial blood flow, cessation of the portal’s flow leads to a compensatory increased flow in the corresponding arterial territory[17] that may cause the tumor progress.

Recently, Ogata et al[15] have reported in a controlled trial the feasibility and efficacy of a sequential arterial-portal embolization, TACE followed by PVE after a 3 wk delay, before major liver resection in cirrhotic patients with HCC. When compared to PVE alone, this procedure offers a significantly higher rate of complete tumor necrosis (83% vs 5%, P < 0.001), a higher 5-year disease-free survival rate (37% vs 19%, P = 0.041) with a similar rate of morbidity. In this report the authors confirmed that complete tumor necrosis can be obtained by its complete blood flow privation (arterial and portal) and highlight the potential benefit of this sequence in term of prognosis. Moreover, in their report, the Beajou’s group[18] suggests that sequential embolization could effectively be an appropriate treatment itself in patients in whom surgery is precluded due to a poor degree of liver hypertrophy.

In case of unresectable HCC, efficacy of TACE is now admitted[19,20] with a benefit in survival when compared to conservative treatment. Yet, TACE alone leads to around 50% of complete tumour necrosis[21-23] whereas this rate is over 80% after sequential arterial-portal embolization and this may have an impact on survival curves[16,18]. Aoki et al[16] obtained a necrosis rate superior to 70% in 12/17 (71%) whereas Yamakada et al[21] observed a complete tumoral necrosis in 7/9 (78%) of the resected specimen after a sequential arterio-portal procedure with 1, 3 and 5 years survival rates of 87%, 72% and 51%, respectively.

Even though portal vein thrombosis, which is a frequent complication of HCC, is considered to be an absolute contraindication to TACE, due to increased risk of post procedure liver failure or infarction, efficacy and safety of TACE in such cases have been reported[25] in selected patients. Taken together, these observations suggest a good tolerance of liver parenchyma to ischemia when interval between portal and arterial occlusion is delayed[18]. Ogata et al[15] who have suggested a minimum of 3 wk between both procedures had lesser morbidity and aminotransferase levels as compared to Aoki et al[16] who performed both embolizations within a period of 7 d.

In the case herein reported, although our patient
was planned to have a major liver resection we did not perform a preoperative TACE before PVE, which is now systematic in our department. In this particular case, arterial embolization was performed after portal embolization and was indicated to treat a traumatic arterial aneurysm following a peroperative fine needle biopsy. Yet, it was well tolerated, had no consequence on liver function and led to a complete tumor necrosis with a prolonged survival. We agree that a portoarterial sequence is unusual and do not recommend it that way, but this case fully illustrates the synergy of a combined embolization in term of tumor necrosis. We rather recommend a sequential arterio-portal sequence combining TACE and PVE as previously described, with a 3 wk delay between both procedures. In this view, we assume that tolerance is related to the sequence and its timing whereas efficacy is related to both, arterial and portal, HCC vascular exclusion.

Our report aims at giving further support to the combination of TACE and portal embolization in the treatment of voluminous HCC that cannot be treated by surgery or alternative therapy such as radiofrequency as previously hypothesized by others. We assume that cirrhotic liver parenchyma has a relatively good tolerance to arterial and portal ischemia when the interval between both vascular occlusions is delayed (at least 3 wk). Proven efficacy of TACE might be enhanced by a combined sequential PVE. Patients With large HCC, not suitable for surgery or local ablative therapy, could effectively be treated with combined arterio-portal embolization with a limited morbidity and a likely benefit in survival.
REFERENCES

1. Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology* 2002; 35: 519-524

2. Trinchet JC. Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. *J Hepatol* 1997; 27: 756-765

3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; 35: 421-430

4. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. *Ann Surg* 1995; 221: 291-298

5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; 362: 1218-1224

6. Fan ST. Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy. *Hepatogastroenterology* 2002; 49: 17-20

7. Makuchuki M, Belghiti J, Belli G, Fan ST, Lau JW, Ringe B, Strasberg SM, Vauthen JN, Yamaoka Y, Yasamuki S. IHPBA concordant classification of primary liver cancer: working group report. *J Hepatobiliary Pancreat Surg* 2003; 10: 26-30

8. Takayasu A, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuchuki M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology* 2006; 131: 461-469

9. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. *N Engl J Med* 1995; 332: 1256-1261

10. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology* 1998; 27: 1578-1583

11. Pelletier G, Durecues M, Gay F, Luboinski M, Hagege H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. *Groupe CHC. J Hepatol* 1998; 29: 129-134

12. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; 359: 1734-1739

13. Makuchuki M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. *Surgery* 1990; 107: 521-527

14. Di Stefano DR, de Baece T, Denys A, Hakime A, Gorin G, Gillet M, Saric J, Trillaud H, Petit P, Bartoli JM, Elias D, Delpero JR. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. *Radiology* 2005; 234: 625-630

15. Kubota K, Makuchuki M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. *Hepatology* 1997; 26: 1176-1181

16. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, Kokudo N, Makuchuki M. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. *Arch Surg* 2004; 139: 766-774

17. Nagino M, Nimmura Y, Kamiya J, Kanai M, Hayakawa N, Yamamoto H. Immediate increase in arterial blood flow in embolized hepatic segments after portal vein embolization: CT demonstration. *AJR Am J Roentgenol* 1998; 171: 1037-1039

18. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal venous embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. *Br J Surg* 2006; 93: 1091-1098

19. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; 37: 429-442

20. Camma C, Schepis F, Orlando A, Albanese M, Shahled L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology* 2002; 224: 47-54

21. Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. *Cancer* 2000; 89: 2606-2612

22. Harada T, Matsuo K, Inoue T, Tamesue S, Inoue T, Nakamura H. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? *Ann Surg* 1996; 224: 4-9

23. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. *J Hepatol* 2000; 33: 359-366

24. Yamakado K, Nakatsuka A, Tanaka N, Matsumura K, Takase K, Takeda K. Long-term follow-up arterial chemoembolization combined with transportal ethanol injection used to treat hepatocellular carcinoma. *J Vasc Interv Radiol* 1999; 10: 641-647

25. Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. *J Vasc Interv Radiol* 2005; 16: 1653-1659

S- Editor Li DL  L- Editor Alpini GD  E- Editor Lin YP